Endocrine Abstracts

IntroductionNowadays thrombopoietin receptor agonists (TPO-RAs) represent a promising approach for the patients with immune thrombocytopenia (ITP). Usage of two licensed TPO-RAs, romiplostim and eltrombopag, provide efficient support of ITP patients´ platelet count and, as a consequence, better control of disease. Both agents have an acceptable toxicity profile, but there are several another disadvantages in terms of usage of these drugs such as cos...